Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

BioPharmaceuticals Revenue: $21.9 billion in 2024, up 21%. Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

So if actually AstraZeneca was found liable, a fine of between one to five times the amount of avoided import duties could have to be paid by AstraZeneca. We are continuing to cooperate with the ...

AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...

Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE ...